Artificial liver support in acute and acute-on-chronic liver failure

Current Opinion in Critical Care - Tập 25 Số 2 - Trang 187-191 - 2019
Fin Stolze Larsen1,2
1Department of Hepatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
2to Professor Fin Stolze Larsen, Department of Hepatology A-3163, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark. E-mail: [email protected]

Tóm tắt

Purpose of review Liver failure is a life-threatening condition, and an artificial liver is highly desirable to replace the failing liver-functions in the waiting time for liver regeneration to happen or until liver transplantation can be undertaken. This review focuses on the efficacy of using artificial extracorporeal liver support devices. Recent findings Artificial liver support devices such as the molecular adsorbent recirculating system (MARS), fractionated plasma separation and adsorption, and therapeutic plasma exchange (TPE) are well tolerated. MARS and TPE improve systemic haemodynamics and the grade of hepatic encephalopathy. However, randomized, controlled trials of MARS and fractionated plasma separation and adsorption have failed to show improvement in survival in patients with acute liver failure (ALF) and patients with acute-on-chronic liver failure (ACLF). Only TPE improves survival in patients with ALF by ameliorate the release of ammonia, damage-associated molecular patterns and sB7 (CD80/86) from the necrotic liver. No randomized, controlled trials on survival in patients with ACLF using TPE have been done. Summary Liver support systems such as MARS and TPE may temporarily improve systemic haemodynamics and the degree of encephalopathy. However, TPE is the only procedure that improves survival in patients with ALF. The role of TPE in ACLF remains unknown.

Từ khóa


Tài liệu tham khảo

Bernsmeier, 2018, CD14(+) CD15(-) HLA-DR(-) myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure, Gut, 67, 1155, 10.1136/gutjnl-2017-314184

Khamri, 2017, Increased expression of cytotoxic T-lymphocyte-associated protein 4 by T cells, induced by B7 in sera, reduces adaptive immunity in patients with acute liver failure, Gastroenterology, 153, 263, 10.1053/j.gastro.2017.03.023

Selvapatt, 2014, Understanding infection susceptibility in patients with acute-on-chronic liver failure, Intensive Care Med, 40, 1363, 10.1007/s00134-014-3349-x

Larsen, 2016, High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial, J Hepatol, 64, 69, 10.1016/j.jhep.2015.08.018

Demetriou, 2004, Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure, Ann Surg, 239, 660, 10.1097/01.sla.0000124298.74199.e5

Thompson, 2018, Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial, Liver Transpl, 24, 380, 10.1002/lt.24986

Denis, 1978, Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high permeability membrane, Gut, 19, 787, 10.1136/gut.19.9.787

Slack, 2014, Ammonia clearance with haemofiltration in adults with liver disease, Liver Int, 34, 42, 10.1111/liv.12221

Davenport, 1991, Continuous vs. intermittent forms of haemofiltration and/or dialysis in the management of acute renal failure in patients with defective cerebral autoregulation at risk of cerebral oedema, Contrib Nephrol, 93, 225, 10.1159/000420225

Davenport, 1993, Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure, Crit Care Med, 21, 328, 10.1097/00003246-199303000-00007

Cardoso, 2017, Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure, Hepatology, 31

Saliba, 2013, Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial, Ann Intern Med, 159, 522, 10.7326/0003-4819-159-8-201310150-00005

Banares, 2013, Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial, Hepatology, 57, 1153, 10.1002/hep.26185

Sen, 2004, Albumin dialysis: a new therapeutic strategy for intoxication from protein-bound drugs, Intensive Care Med, 30, 496, 10.1007/s00134-003-2141-0

Stange, 1999, Molecular Adsorbent Recycling System (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support, Artif Organs, 23, 319, 10.1046/j.1525-1594.1999.06122.x

Sorkine, 2001, Role of the Molecular Adsorbent Recycling System (MARS) in the treatment of patients with acute exacerbation of chronic liver failure, Crit Care Med, 29, 1332, 10.1097/00003246-200107000-00006

Mitzner, 2001, Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system, Ther Apher, 5, 417, 10.1046/j.1526-0968.2001.00388.x

Butterworth, 2003, Role of circulating neurotoxins in the pathogenesis of hepatic encephalopathy: potential for improvement following their removal by liver assist devices, Liver Int, 23, 5, 10.1034/j.1478-3231.23.s.3.1.x

Schmidt, 2004, Effect of treatment with the Molecular Adsorbents Recirculating System on arterial amino acid levels and cerebral amino acid metabolism in patients with hepatic encephalopathy, Scand J Gastroenterol, 39, 974, 10.1080/00365520410003227

Schmidt, 2001, Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure, Liver Transpl, 7, 1034, 10.1053/jlts.2001.29108

Hassanein, 2007, Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis, Hepatology, 46, 1853, 10.1002/hep.21930

Schmidt, 2003, Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial, Liver Transpl, 9, 290, 10.1053/jlts.2003.50051

Heemann, 2002, Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study, Hepatology, 36, 949

Laleman, 2006, Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure, Crit Care, 10, R108, 10.1186/cc4985

Krisper, 2005, In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation, J Hepatol, 43, 451, 10.1016/j.jhep.2005.02.038

Oppert, 2009, Extracorporeal liver support therapy with Prometheus in patients with liver failure in the intensive care unit, Ther Apher Dial, 13, 426, 10.1111/j.1744-9987.2009.00761.x

Rifai, 2003, Prometheus—a new extracorporeal system for the treatment of liver failure, J Hepatol, 39, 984, 10.1016/S0168-8278(03)00468-9

Kribben, 2012, Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure, Gastroenterology, 142, 782, 10.1053/j.gastro.2011.12.056

Dethloff, 2008, Effect of Prometheus liver assist system on systemic hemodynamics in patients with cirrhosis: a randomized controlled study, World J Gastroenterol, 14, 2065, 10.3748/wjg.14.2065

Kondrup, 1992, High volume plasma exchange in fulminant hepatic failure, Int J Artif Organs, 15, 669, 10.1177/039139889201501110

Larsen, 1995, Systemic vascular resistance during high-volume plasmapheresis in patients with fulminant hepatic failure: relationship with oxygen consumption, Eur J Gastroenterol Hepatol, 7, 887

Clemmesen, 1997, Haemodynamic changes after high-volume plasmapheresis in patients with chronic and acute liver failure, Eur J Gastroenterol Hepatol, 9, 55, 10.1097/00042737-199701000-00014

Larsen, 1996, Cerebral blood flow, oxygen metabolism and transcranial Doppler sonography during high-volume plasmapheresis in fulminant hepatic failure, Eur J Gastroenterol Hepatol, 8, 261, 10.1097/00042737-199603000-00014

Clemmesen, 1999, Hepatic blood flow and splanchnic oxygen consumption in patients with liver failure. Effect of high-volume plasmapheresis, Hepatology, 29, 347, 10.1002/hep.510290206

Clemmesen, 2001, Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure, Am J Gastroenterol, 96, 1217, 10.1111/j.1572-0241.2001.03706.x

Thông tin
Thông tin xuất bản

Current Opinion in Critical Care

Tập 25 Số 2

187-191

Thông tin tác giả